215,902 Shares in Coherus BioSciences, Inc. (NASDAQ:CHRS) Bought by Tyche Wealth Partners LLC

Tyche Wealth Partners LLC purchased a new stake in Coherus BioSciences, Inc. (NASDAQ:CHRS) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 215,902 shares of the biotechnology company’s stock, valued at approximately $719,000.

Several other large investors have also bought and sold shares of CHRS. Eagle Bay Advisors LLC grew its stake in shares of Coherus BioSciences by 136.1% in the 2nd quarter. Eagle Bay Advisors LLC now owns 3,891 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 2,243 shares in the last quarter. Captrust Financial Advisors grew its position in Coherus BioSciences by 1,461.0% in the 1st quarter. Captrust Financial Advisors now owns 2,404 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 2,250 shares in the last quarter. Dorsey & Whitney Trust CO LLC purchased a new position in Coherus BioSciences in the third quarter valued at about $39,000. Princeton Global Asset Management LLC bought a new position in shares of Coherus BioSciences during the 3rd quarter valued at approximately $39,000. Finally, Federated Hermes Inc. increased its stake in shares of Coherus BioSciences by 55.0% during the 3rd quarter. Federated Hermes Inc. now owns 4,223 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 1,498 shares during the last quarter. 72.82% of the stock is currently owned by institutional investors.

Coherus BioSciences Price Performance

Shares of NASDAQ CHRS traded up $0.04 during mid-day trading on Wednesday, hitting $2.19. The company had a trading volume of 123,441 shares, compared to its average volume of 3,883,745. Coherus BioSciences, Inc. has a 1 year low of $1.43 and a 1 year high of $8.34. The stock’s 50-day moving average price is $2.41 and its 200-day moving average price is $2.55.

Coherus BioSciences (NASDAQ:CHRS) last announced its quarterly earnings results on Wednesday, March 13th. The biotechnology company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.39). The firm had revenue of $91.52 million during the quarter, compared to analysts’ expectations of $105.30 million. Equities research analysts anticipate that Coherus BioSciences, Inc. will post -0.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on CHRS. Truist Financial reduced their price objective on Coherus BioSciences from $12.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, January 23rd. Robert W. Baird cut their price target on Coherus BioSciences from $11.00 to $9.00 and set an “outperform” rating for the company in a research note on Tuesday, January 23rd. Finally, HC Wainwright lowered their price objective on Coherus BioSciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Wednesday, March 20th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $9.29.

Coherus BioSciences Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.